Riskpilot← Back to searchSign inGet full accessDispersome IP ApS
APSActiveCVR 44931478Fruebjergvej 3Manufacture of pharmaceutical preparations · NACE 2120Est. 2024— employees
Revenue 2025
DKK -1,9M
EBITDA margin
100.0%
Equity ratio
67.8%
Financial strength
Net profit 2025
DKK -2,3M
| Revenue | DKK -1,9M | — |
| EBITDA | DKK -1,9M | — |
| Net profit | DKK -2,3M | — |
| Total assets | DKK 25,2M | — |
| Equity | DKK 17,1M | — |
| Employees | — | — |
Legal name
Dispersome IP ApS
CVR number
44931478
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
27. juni 2024
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og et bestyrelsesmedlem i forening, af to bestyrelsesmedlemmer eller af bestyrelsen.
Company purpose
Selskabets formål er at eje patenter, patentansøgnin-ger, licensaftaler og andre IP-rettigheder.
Address
Fruebjergvej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2025 |
|---|---|
| Revenue | -1.882 |
| Staff expenses | -0 |
| EBITDA | -1.882 |
| Depreciation & amort. | -1.005 |
| EBIT | -2.887 |
| Net financials | -21 |
| Profit before tax | -2.907 |
| Tax | -640 |
| Net profit | -2.268 |
| Item | 2025 |
|---|---|
| Total assets | 25.169 |
| Equity | 17.053 |
| Long-term debt | 0 |
| Short-term debt | 3.317 |
| Total debt | 3.317 |
EBITDA margin
-188219700.0%
This company
15.8%
Market median
-1191264024% vs market
20252025
Equity ratio
67.8%
This company
38.2%
Market median
+77% vs market
20252025
Return on equity
-13.3%
This company
18.4%
Market median
-172% vs market
20252025
Net profit margin
-226784500.0%
This company
8.1%
Market median
-2799808742% vs market
20252025
Asset turnover
-0.07×
This company
1.12×
Market median
-106% vs market
20252025
Debt / equity
0.48×
This company
0.62×
Market median
+23% vs market
20252025
- Annual report 2025Filed via CVR / Virk · Period 2024-06-27 – 2025-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CB Management | Management | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Zerion Pharma A/S | Company | 50.0% | 50.0% | 2024 |
| Individual | 50.0% | 50.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
WIBORG INTERNATIONAL HOLDING ApS
Dispersome IP ApS Board members of Dispersome IP ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christoph Brücher | Management | 0 companies |
| Jakob Dynnes Hansen | Board of Directors | 0 companies |
| Márcio Milton Nunes Temtem | Board of Directors | 0 companies |
| Ole Sylvester-Hvid Wiborg | Chairman | 0 companies |
| Korbinian Arthur Maria Löbmann | Board of Directors | 0 companies |